A new US biotech, Aiolos Bio, has drawn in an impressive $245 million in Series A financing that will help it complete clinical testing of lead drug AIO-001 for moderate-to-severe asthma.

Tuesday’s round brings Bain Capital Life Sciences’ fundraising total to around $6.7 billion since its founding in 2016. Many ...

Hyacinths are an old-fashioned springtime favorite with brightly-colored spikes of flowers and an intense fragrance that ...

GSK has taken another step towards rebuilding its respiratory pipeline with a $1.4 billion agreement to buy Aiolos Bio and its lead drug AIO-001 for asthma and other indications. The deal ...

In February, inflammatory disease specialist Aiolos Bio was acquired by GSK in a $1.4bn deal. Aiolos had launched not long ...

The fund is Bain’s fourth and follows several recent acquisitions of some of its portfolio companies, among them Jnana ...

GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the ...

Hyacinth flowers are low-maintenance spring blooms that burst into strikingly beautiful colors. Here's how to plant the fall ...

Theme music is by Aiolos Rue. Interviews are recorded at the Liberal Arts ITS recording studio. Elements of the cover image for this episode were generated using Midjourney and Photoshop’s generative ...

Bain Capital Life Sciences has closed its fourth fund, securing approximately $3 billion, including $2.5 billion from investors and additional contributions from Bain partners, employees, and ...

GSK has reported positive results from its phase II trial for an mRNA seasonal influenza vaccine candidate, showing strong immune responses again ...